Cancer treatment

Patients receiving chemotherapy
#Adverse event #Cancer treatment #Chemotherapy #MHRA #NHS #Unlicensed drug

Patient dies after receiving unlicensed drug

A cancer patient died and three others were hospitalised in the UK after they were administered an unlicensed version of chemotherapy cabazitaxel. According to The Guardian, which reported on the incident, the problem was caused by an issue at private healthcare company Sciensus’… Read More

#News #Trending News

Medical laboratory
#AACR 2023 #Cancer research #Cancer treatment #Oncology #Phase III trial #Rare cancers

Immune checkpoint inhibitor improved survival in rare cancer

The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the Phase III KEYNOTE-966 clinical trial. The results were presented at the AACR Annual Meeting 2023, held April 14-19 and… Read More

#Cancer Research #News

Lung cancer
#AACR 2023 #Cancer research #Cancer treatment #Lung cancer #Oncology #Phase III trial

Therapy represents ‘new treatment paradigm’ for lung cancer

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone. The results from the Phase III placebo-controlled AEGEAN… Read More

#Cancer Research #News #Trending News

Liver cancer
#AACR 2023 #Cancer research #Cancer treatment #Liver cancer #Oncology #Phase III trial

Results revealed for ‘practice-changing’ combination liver cancer therapy

Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to the results from a Phase III trial. The results of the IMbrave050 clinical trial were presented at the AACR Annual Meeting 2023,… Read More

#Cancer Research #News

Cancer research
#Animal models #Cancer research #Cancer treatment #Oncology #The Institute of Cancer Research

First-in-class HSF1 pathway drug shrinks tumours in mice

A new, oral, first-in-class experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows. The drug, which is now called NXP800 and has already entered a Phase I clinical trial, was… Read More

#Cancer Research #News

Cancer cell
#Breast cancer #Cancer research #Cancer treatment #Drug development #Drug discovery #Oncology

New global cancer research DDW eBook

This latest ebook sponsored by Sino Biological features insight on how the global drug discovery and development sector is making breakthroughs in cancer research.  Download this exclusive eBook to learn more about:  The global developments tackling the burden of cancer  … Read More

#News

Global cancer research eBook
#Breast cancer #Cancer research #Cancer treatment #Drug development #Drug discovery #Oncology

Global cancer research: Where are the breakthroughs?

This latest eBook sponsored by Sino Biological features insight on how the global drug discovery and development sector is making breakthroughs in cancer research.  Download this exclusive eBook to learn more about:  The global developments tackling the burden of cancer   Advances and challenges… Read More

#DDW eBooks #Intelligence

Knee x-ray
#Cancer research #Cancer treatment #Genetics / genomics #Oncology #Preclinical investigations #University of East Anglia

Bone cancer drug increases survival rates by 50%

Researchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer. The study shows how a breakthrough drug called CADD522 blocks a gene associated with driving the cancer’s spread in mice implanted with… Read More

#Cancer Research #Editor's Choice #News

Urinary system
#Cancer treatment #China #Oncology #Phase II trial #Regulatory

Astellas’ urothelial cancer drug approved in China

China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for enfortumab vedotin for urothelial cancer. The approval is in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. Read More

#News #Regulatory

#Cancer research #Cancer treatment #CAR-T #Cell therapy #Drug discovery #Epigenetics #Immunotherapy #Oncology

New episode of the DDW Highlights podcast available

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As well as providing extensive coverage of the … Read More

#News

#Cancer research #Cancer treatment #CAR-T #Cell therapy #Drug discovery #Epigenetics #Immunotherapy #Oncology

This week in drug discovery (27 February – 3 March)

News round-up for 27 February – 3 March by DDW Digital Content Editor Diana Spencer.  As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a… Read More

#News

Glasgow, Scotland
#Cancer treatment #Health inequalities #Oncology #Personalised medicine #Precision medicine #University of Glasgow

Commission tackles global access to precision cancer treatments

A team of experts from the University of Glasgow will lead a new international effort to improve cancer control and reduce global health inequalities.  Spearheading the new Lancet Oncology Commission focused on cancer genomics and precision oncology, Glasgow researchers will lead an international team of experts over… Read More

#News

#Biologics #Cancer research #Cancer treatment #Immunology #Oncology

Biologics and living drugs: entering a new era of cancer treatment

This paid-for advertorial by Sphere Fluidics appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Modern drug development has expanded from chemist-made substances to biologics and cell-based therapies. Despite the progress of the last two decades, we are only scratching the surface of what is possible and… Read More

#Cancer Research #Exclusive Content

Patients receiving chemotherapy
#Cancer treatment #Chemotherapy #Hearing Loss #Phase II trial #Sensorion

Drug could prevent chemotherapy-induced hearing loss

Biotechnology company Sensorion has enrolled the first patient in its Phase IIa Proof of Concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity.  Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity,… Read More

#Cancer Research #News

Testing acidity in the lab
#Cancer immunotherapy #Cancer research #Cancer treatment #Cytokines #Immunotherapy #Tumours

Acid discovery raises hopes of improved immunotherapies

The acidity of tumours impairs the effectiveness of anti-cancer therapies, according to a new study that could lead to a new generation of immunotherapy treatments.  Tumours have a more acidic environment (pH 6.5) than normal, healthy tissues (pH 7.2). New research has shown for the first time… Read More

#Cancer Research #News

Antibodies attacking cancer cell
#Bispecific Antibodies #Cancer research #Cancer treatment #Mergers and acquisitions #Monoclonal antibodies #Oncology

Jazz acquires rights to HER2-targeted bispecific antibody

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. Zymeworks will receive a $50 million upfront payment, a second payment of $325 million, at Jazz’s option, and further potential… Read More

#Cancer Research #News